title: Ceftaroline-heteroresistant Staphylococcus aureus.
abstract: Heteroresistance refers to the presence, within a large population of antimicrobial-susceptible microorganisms, of subpopulations with lesser susceptibilities. Ceftaroline is a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). The aim of this study was to detect the prevalence of ceftaroline heteroresistance in vitro in a select group of S. aureus strains. There were 57 isolates selected for evaluation, 20 MRSA, 20 vancomycin-intermediate S. aureus (VISA), 7 daptomycin-nonsusceptible S. aureus (DNSSA), 6 linezolid-nonsusceptible S. aureus (LNSSA), and 4 heteroresistant VISA (hVISA) isolates. MICs and minimal bactericidal concentrations were determined using the broth microdilution method according to CLSI guidelines. All of the isolates were analyzed by pulsed-field gel electrophoresis. The staphylococcal cassette chromosome mec element (SCCmec) types were determined by a multiplex PCR. Population analysis profiles (PAPs) were performed to determine heteroresistance for all of the isolates using plates made by adding various amounts of ceftaroline to brain heart infusion agar. The frequencies of resistant subpopulations were 1 in 10(4) to 10(5) organisms. We determined that 12 of the 57 (21%) isolates tested were ceftaroline-heteroresistant S. aureus (CHSA). CHSA occurred among strains with reduced susceptibilities to vancomycin, daptomycin, and linezolid but occurred in none of the USA-300 isolates tested. Evaluation of the heteroresistant strains demonstrated that the phenotype was unstable. Further studies are needed to determine whether CHSA has a role in clinical failures and to determine the implications of our study findings.
authors.affiliation: St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Stephanie N
authors.initials: SN
authors.lastname: Saravolatz
authors.affiliation: St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Hayley
authors.initials: H
authors.lastname: Martin
authors.affiliation: St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Joan
authors.initials: J
authors.lastname: Pawlak
authors.affiliation: St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Leonard B
authors.initials: LB
authors.lastname: Johnson
authors.affiliation: St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA louis.saravolatz@stjohn.org.
authors.forename: Louis D
authors.initials: LD
authors.lastname: Saravolatz
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D016521:Electrophoresis, Gel, Pulsed-Field; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology; D020713:Vancomycin Resistance; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D017576:Daptomycin; D000069349:Linezolid; D014640:Vancomycin; D000097583:Ceftaroline